FH-EARLY is at the forefront of advancing research and clinical care for Familial Hypercholesterolaemia (FH). Through pioneering studies, cutting-edge data science, and open sharing of results, we’re building the foundations for earlier diagnosis, personalised treatment, and better outcomes for everyone affected by FH.

We are running two major interventional clinical studies to advance FH care:

• FH Study: Evaluating how the signature biomarker can help optimise treatment for people with FH.
• Secondary MI Prevention Study: Using the biomarker in patients recovering from myocardial infarction (heart attack) to support better long-term outcomes.

Want to take part?

Find out about study eligibility, how to participate, and follow our study progress as results emerge.

FH-EARLY brings together high-quality, FAIR-aligned data from four clinical cohorts and multiple ‘omics’ platforms (genomics, lipidomics, transcriptomics). Our research is focused on:

• Functional characterisation of thousands of FH-related gene variants
• Multi-omic data fusion to understand the complex biology of FH
• Developing new polygenic risk scores to better predict and manage cardiovascular risk

This robust data foundation powers our digital tools and underpins more precise, individualised care for people with FH.

As our research progresses, we will share open-access publications, clinical findings, and data repositories here. All lay summaries will be co-created with patients to make scientific advances accessible and relevant.

Coming soon:
Explore our latest results, download publications, and discover how FH-EARLY is driving change in FH care.

Interested in participating in our studies or contributing your expertise? Contact us to learn more